Impact of Platelet Reactivity on One-year Clinical Outcomes after Endovascular Therapy for Femoropopliteal Lesions

Dual antiplatelet therapy with aspirin plus P2Y12 inhibitor for at least 1 month after endovascular therapy (EVT) is recommended in symptomatic lower extremity arterial disease (LEAD) with femoropopliteal (FP) lesions [1]. However, the pharmacodynamic response to antiplatelet medication differs between individuals. In particular, greater individual differences in platelet reactivity to clopidogrel, one of the P2Y12 inhibitors, have been reported compared to aspirin [2]. Several previous studies evaluated the association of platelet reactivity with clinical outcomes in the area of LEAD management, but their conclusions were inconsistent [2-5].
Source: The American Journal of Cardiology - Category: Cardiology Authors: Tags: Brief report Source Type: research